雪榕生物
(300511)
| 流通市值：43.84亿 | | | 总市值：51.46亿 |
| 流通股本：5.46亿 | | | 总股本：6.41亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 678,923,162.65 | 1,987,614,708.05 | 1,324,930,751.78 | 790,674,852.9 |
| 营业收入 | 678,923,162.65 | 1,987,614,708.05 | 1,324,930,751.78 | 790,674,852.9 |
| 二、营业总成本 | 505,757,763.08 | 1,955,920,414.81 | 1,403,701,115.19 | 905,371,491.71 |
| 营业成本 | 450,581,731.92 | 1,716,846,513.77 | 1,226,720,606.52 | 780,898,014.04 |
| 税金及附加 | 5,147,487.72 | 20,532,645.44 | 14,899,124.42 | 9,709,019.65 |
| 销售费用 | 5,406,226.71 | 21,640,168.35 | 14,486,290.96 | 9,058,248.71 |
| 管理费用 | 28,647,149.88 | 136,942,903 | 100,594,021.39 | 69,759,574.61 |
| 研发费用 | 776,371.44 | 3,341,415.84 | 2,365,283.81 | 1,730,731.51 |
| 财务费用 | 15,198,795.41 | 56,616,768.41 | 44,635,788.09 | 34,215,903.19 |
| 其中:利息费用 | 9,423,249.14 | 60,684,635.89 | 44,644,101.28 | 34,518,017.55 |
| 其中:利息收入 | 196,432.26 | 646,799.72 | 266,688.17 | 149,839.5 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 38,348.96 | - | - |
| 加:投资收益 | - | 1,013,061.49 | 1,013,061.49 | 1,013,061.49 |
| 资产处置收益 | 268,167.86 | 16,311,304.25 | 17,348,036.7 | 12,375,039.33 |
| 资产减值损失(新) | - | -16,196,762.52 | -1,058,136.82 | -662,693.74 |
| 信用减值损失(新) | 185,445.85 | -786,190.7 | -202,800.73 | 45,094.22 |
| 其他收益 | 2,331,194.11 | 10,578,024.07 | 8,088,972.65 | 5,550,218.46 |
| 四、营业利润 | 175,950,207.39 | 42,652,078.79 | -53,581,230.12 | -96,375,919.05 |
| 加:营业外收入 | 3,356.72 | 725,111.33 | 385,473.69 | 364,060.65 |
| 减:营业外支出 | 253,788.18 | 4,183,079.03 | 2,251,420.93 | 1,258,691.43 |
| 五、利润总额 | 175,699,775.93 | 39,194,111.09 | -55,447,177.36 | -97,270,549.83 |
| 减:所得税费用 | 48,312.57 | 775,374.64 | 759,982.62 | 3,046.03 |
| 六、净利润 | 175,651,463.36 | 38,418,736.45 | -56,207,159.98 | -97,273,595.86 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 175,651,463.36 | 38,418,736.45 | -56,207,159.98 | -97,273,595.86 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 173,170,360.14 | 29,793,998.17 | -62,348,351.93 | -102,552,021.15 |
| 少数股东损益 | 2,481,103.22 | 8,624,738.28 | 6,141,191.95 | 5,278,425.29 |
| 扣除非经常损益后的净利润 | 170,949,185.49 | 5,178,594.18 | -85,189,552.12 | -120,083,845.73 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.27 | 0.05 | -0.11 | -0.19 |
| (二)稀释每股收益 | 0.27 | 0.05 | -0.11 | -0.19 |
| 八、其他综合收益 | -2,155,034.21 | 1,062,270.97 | 764,947.24 | 741,303.82 |
| 归属于母公司股东的其他综合收益 | -1,297,302.32 | 615,589.41 | 431,503.3 | 428,555.07 |
| 九、综合收益总额 | 173,496,429.15 | 39,481,007.42 | -55,442,212.74 | -96,532,292.04 |
| 归属于母公司股东的综合收益总额 | 171,873,057.82 | 30,409,587.58 | -61,916,848.63 | -102,123,466.08 |
| 归属于少数股东的综合收益总额 | 1,623,371.33 | 9,071,419.84 | 6,474,635.89 | 5,591,174.04 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-16 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |